These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22192883)

  • 21. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.
    Thompson R; Eastman A
    Br J Clin Pharmacol; 2013 Sep; 76(3):358-69. PubMed ID: 23593991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA damage checkpoints: implications for cancer therapy.
    O'Connor PM; Fan S
    Prog Cell Cycle Res; 1996; 2():165-73. PubMed ID: 9552393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting DNA repair mechanisms in cancer.
    Furgason JM; Bahassi el M
    Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reality CHEK: Understanding the biology and clinical potential of CHK1.
    Neizer-Ashun F; Bhattacharya R
    Cancer Lett; 2021 Jan; 497():202-211. PubMed ID: 32991949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel checkpoint 1 inhibitors.
    Prudhomme M
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):55-68. PubMed ID: 18221026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors.
    van Bijsterveldt L; Durley SC; Maughan TS; Humphrey TC
    Clin Cancer Res; 2021 Feb; 27(4):937-962. PubMed ID: 33257428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies.
    Puigvert JC; Sanjiv K; Helleday T
    FEBS J; 2016 Jan; 283(2):232-45. PubMed ID: 26507796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining DNA damaging agents and checkpoint 1 inhibitors.
    Prudhomme M
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):435-8. PubMed ID: 15379699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer.
    Dent P
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1095-1100. PubMed ID: 31783714
    [No Abstract]   [Full Text] [Related]  

  • 30. Culture at a Higher Temperature Mildly Inhibits Cancer Cell Growth but Enhances Chemotherapeutic Effects by Inhibiting Cell-Cell Collaboration.
    Zhu S; Wang J; Xie B; Luo Z; Lin X; Liao DJ
    PLoS One; 2015; 10(10):e0137042. PubMed ID: 26495849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting cell cycle regulation in cancer therapy.
    Diaz-Moralli S; Tarrado-Castellarnau M; Miranda A; Cascante M
    Pharmacol Ther; 2013 May; 138(2):255-71. PubMed ID: 23356980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.
    Mills CC; Kolb EA; Sampson VB
    Cancer Res; 2018 Jan; 78(2):320-325. PubMed ID: 29311160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.
    Ashwell S; Janetka JW; Zabludoff S
    Expert Opin Investig Drugs; 2008 Sep; 17(9):1331-40. PubMed ID: 18694366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boromycin abrogates bleomycin-induced G2 checkpoint.
    Arai M; Koizumi Y; Sato H; Kawabe T; Suganuma M; Kobayashi H; Tomoda H; Omura S
    J Antibiot (Tokyo); 2004 Oct; 57(10):662-8. PubMed ID: 15638327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer.
    Gorecki L; Andrs M; Korabecny J
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
    Lodovichi S; Cervelli T; Pellicioli A; Galli A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.
    Carrassa L; Damia G
    Cancer Treat Rev; 2017 Nov; 60():139-151. PubMed ID: 28961555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cycle checkpoints and their inactivation in human cancer.
    Molinari M
    Cell Prolif; 2000 Oct; 33(5):261-74. PubMed ID: 11063129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
    Velic D; Couturier AM; Ferreira MT; Rodrigue A; Poirier GG; Fleury F; Masson JY
    Biomolecules; 2015 Nov; 5(4):3204-59. PubMed ID: 26610585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
    Babiker HM; McBride A; Cooke LS; Mahadevan D
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1063-1072. PubMed ID: 28745064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.